Dapansutrile is under clinical development by Olatec Therapeutics and currently in Phase II for Melanoma. According to GlobalData, Phase II drugs for Melanoma have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Dapansutrile’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Dapansutrile overview

Dapansutrile (OLT-1177) is under development for the treatment of moderate to severe pain associated with osteoarthritis of the knee, acute gout flares, systolic heart failure, melanoma, Alzheimer’s disease, spinal cord injury (SCI), multiple sclerosis (MS), type 2 diabetes and Parkinson’s disease (PD). The drug candidate is administered topically in the form of gel and orally as capsules. It acts by targeting the NLRP3 inflammasome.

It was also under development for the treatment of COVID-19 symptoms and evidence of early cytokine release syndrome, Schnitzler's syndrome.

Olatec Therapeutics overview

Olatec Therapeutics (Olatec) is a pharmaceutical drug development company. The company specializes in drug development for acute and chronic inflammatory diseases such as arthritis, heart failure, asthma, Alzheimer’s disease, Parkinson’s disease; multiple sclerosis, spinal cord injury, type-2 diabetes, melanoma and breast cancers, among others. Its product offerings include lead compound, dapansutrile inhibits the production of pro-inflammatory cytokines. Its service offering includes clinical trials, research and development, and drug discovery programs. The company operates with an additional office in the Netherlands. Olatec is headquartered in New York, the US.

For a complete picture of Dapansutrile’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.